Company / Profit Margin
NEKTAR THERAPEUTICS Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-297.1%
FY2025
5-year range
-514.0% / -297.1%
FY2021-FY2025
Trend
+3.0%
vs FY2024
Sector context
#114 of 145
Health Care
What the data says
NEKTAR THERAPEUTICS's profit margin of -297.1% is lower than 79% of companies in the Health Care sector (FY2025). Profit Margin has fluctuated over the past 10 years, ranging from -514.0% in FY2023 to 57.1% in FY2020.
Based on SEC 10-K filings.
-297.1% in FY2025 with a 5-year CAGR of -354.2%.
Improved from -514.0% to -297.1% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +102.9pp
- 5-Year Change
- -354.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 145This company -297.1% Sector average -792.7%
▼
+62.5% above sector average
Key checks
Key Insights
- In FY2025, profit margin increased 3.0% year-over-year.
- Currently 495.6pp above the Health Care sector average.
- Peak profit margin was recorded in FY2020.
- Lowest profit margin in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -297.1% | +3.0% |
| FY2024 | -306.3% | +40.4% |
| FY2023 | -514.0% | -28.5% |
| FY2022 | -400.0% | +22.2% |
| FY2021 | -514.0% | -1000.4% |
| FY2020 | 57.1% | +281.7% |
| FY2019 | -31.4% | +66.1% |
| FY2018 | -92.8% | +76.3% |
| FY2017 | -391.0% | -1355.8% |
| FY2016 | -26.9% | +23.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026